About

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Lupus Forum content is free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the Lupus Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

EULAR 2024 Content
A two-part series exploring the challenges in treating lupus nephritis

NEW Monthly literature search podcasts – available now

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss the efficacy and safety of upadacitinib and elsubrutinib combination and monotherapy, as well as the association of LLDAS with improved outcomes in SLE.

Latest Updates

Publications ▼
All
Publication thumbnail: Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial

Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial

Publication thumbnail: Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

Publication thumbnail: Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis

Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis

Publication thumbnail: Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement

Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement

Steering Committee